Lazard Asset Management
RCEL icon

Lazard Asset Management’s Avita Medical RCEL Stock Holding History

Lazard Asset Management’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,973
Closed -$15K – 2226
2025
Q2 		$15K Buy
+2,973
New +$21.6K ﹤0.01% 2142
2025
Q1 		– Sell
-1,142
Closed -$14K – 2528
2024
Q4 		$14K Buy
1,142
+1,014
+792% +$12K ﹤0.01% 2091
2024
Q3 		$1K Buy
+128
New +$1.2K ﹤0.01% 2197
2024
Q2 		– Sell
-5,428
Closed -$87K – 2391
2024
Q1 		$87K Sell
5,428
-388
-7% -$6.28K ﹤0.01% 1582
2023
Q4 		$79K Buy
5,816
+406
+8% +$4.65K ﹤0.01% 1755
2023
Q3 		$79K Hold
5,410
– – ﹤0.01% 1710
2023
Q2 		$92K Buy
5,410
+2,643
+96% +$38.8K ﹤0.01% 1610
2023
Q1 		$38K Buy
+2,767
New +$29.4K ﹤0.01% 1874
2021
Q4 		– Sell
-3,724
Closed -$65K – 2426
2021
Q3 		$65K Buy
+3,724
New +$70.3K ﹤0.01% 1567

Other funds holding RCEL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

Lazard Asset Management's RCEL Position: Q3 2025 in Review

Lazard Asset Management sold out of Avita Medical (RCEL) in Q3 2025, closing a stake of 2,973 shares — an estimated $15K sold.

Lazard Asset Management first reported a position in RCEL in Q3 2021 and held it in 9 quarters. The position peaked at $92K in Q2 2023. 76 funds tracked by Wall St. Rank hold RCEL as of Q3 2025.

  • Lazard Asset Management reported no remaining Avita Medical position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 2,973 Avita Medical shares in Q3 2025, an estimated $15K.
  • Lazard Asset Management first reported a position in Avita Medical in Q3 2021 and held it in 9 quarters.
  • Lazard Asset Management's Avita Medical position peaked at $92K in Q2 2023.
  • 76 funds tracked by Wall St. Rank held Avita Medical as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.